Capital Asset Advisory Services’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Asset Advisory Services’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-147	Closed	-$11K	–	599
2021 Q3	$11K	Hold	147	–	–	﹤0.01%	592
2021 Q2	$14K	Buy	+147	New	+$12.5K	﹤0.01%	607
2021 Q1	–	Sell	-240	Closed	-$22K	–	717
2020 Q4	$22K	Buy	+240	New	+$19.1K	﹤0.01%	832

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Capital Asset Advisory Services's ARKG Position: Q4 2021 in Review

Capital Asset Advisory Services sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 147 shares — an estimated $11K sold.

Capital Asset Advisory Services first reported a position in ARKG in Q4 2020 and held it in 3 quarters. The position peaked at $22K in Q4 2020. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

Capital Asset Advisory Services reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
Capital Asset Advisory Services sold 147 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $11K.
Capital Asset Advisory Services first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 3 quarters.
Capital Asset Advisory Services's ARK Genomic Revolution ETF position peaked at $22K in Q4 2020.
460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Capital Asset Advisory Services's 13F filing for Q4 2021, filed 4 Feb 2022.